Peroxiredoxin 6 interferes with TRAIL-induced death-inducing signaling complex formation by binding to death effector domain caspase

Cell Death and Differentiation

Volumn 18, Issue 3, 2011, Pages 405-414

  Choi, H ^a   Chang, J W ^a   Jung, Y K ^a  

^a Seoul National University   (South Korea)

Author keywords

caspase 10; caspase 8; DISC; metastasis suppressor; peroxiredoxin 6; TRAIL

Indexed keywords

APOPTOSIS INHIBITOR; CALCIMYCIN; CASPASE 10; CASPASE 8; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; DEATH EFFECTOR DOMAIN; ETOPOSIDE; PEPTIDES AND PROTEINS; PEROXIREDOXIN 6; STAUROSPORINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; DOWN REGULATION; DRUG ACTIVITY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; HELA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOPRECIPITATION; METASTASIS; MUTAGENESIS; PLASMID; PRIORITY JOURNAL; PROTEIN INTERACTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH CANCER; UPREGULATION;

CASPASE 10; CASPASE 8; CELL DEATH; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HELA CELLS; HUMANS; NEOPLASM METASTASIS; PEROXIREDOXIN VI; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 79951681506     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2010.113     Document Type: Article

References (40)

1. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479-489. (Pubitemid 27508237)
2. Thomas LR, Henson A, Reed JC, Salsbury FR, Thorburn A. Direct binding of Fas-associated death domain (FADD) to the tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 is regulated by the death effector domain of FADD. J Biol Chem 2004; 279: 32780-32785. (Pubitemid 39014737)
3. Sprick MR, Rieser E, Stahl H, Grosse-Wilde A, Weigand MA, Walczak H. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J 2002; 21: 4520-4530. (Pubitemid 34984339)
4. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-163. (Pubitemid 29068521)
5. Finnberg N, Klein-Szanto AJ, El-Deiry WS. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest 2008; 118: 111-123.
6. Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001; 7: 94-100. (Pubitemid 32095647)
7. Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008; 133: 693-703. (Pubitemid 351636305)
8. Varfolomeev EE, Schuchmann M, Luria V, Chiannilkulchai N, Beckmann JS, Mett IL et al. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 1998; 9: 267-276. (Pubitemid 28400040)
9. Olson NE, Graves JD, Shu GL, Ryan EJ, Clark EA. Caspase activity is required for stimulated B lymphocytes to enter the cell cycle. J Immunol 2003; 170: 6065-6072. (Pubitemid 36682588)
10. Salmena L, Lemmers B, Hakem A, Matysiak-Zablocki E, Murakami K, Au PY et al. Essential role for caspase 8 in T-cell homeostasis and T-cell-mediated immunity. Genes Dev 2003; 17: 883-895. (Pubitemid 36397376)
11. Wang J, Zheng L, Lobito A, Chan FK, Dale J, Sneller M et al. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 1999; 98: 47-58. (Pubitemid 29331195)
12. Chun HJ, Zheng L, Ahmad M, Wang J, Speirs CK, Siegel RM et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 2002; 419: 395-399.
13. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000; 6: 529-535. (Pubitemid 30305902)
14. Shin MS, Kim HS, Kang CS, Park WS, Kim SY, Lee SN et al. Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. Blood 2002; 99: 4094-4099. (Pubitemid 35332052)
15. Rhee SG, Chae HZ, Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med 2005; 38: 1543-1552. (Pubitemid 40726061)
16. 2 activities. J Biol Chem 2000; 275: 28421-28427.
17. Kang SW, Baines IC, Rhee SG. Characterization of a mammalian peroxiredoxin that contains one conserved cysteine. J Biol Chem 1998; 273: 6303-6311. (Pubitemid 28144720)
18. Manevich Y, Sweitzer T, Pak JH, Feinstein SI, Muzykantov V, Fisher AB. 1-Cys peroxiredoxin overexpression protects cells against phospholipid peroxidation-mediated membrane damage. Proc Natl Acad Sci USA 2002; 99: 11599-11604. (Pubitemid 34994445)
19. Wang X, Phelan SA, Forsman-Semb K, Taylor EF, Petros C, Brown A et al. Mice with targeted mutation of peroxiredoxin 6 develop normally but are susceptible to oxidative stress. J Biol Chem 2003; 278: 25179-25190. (Pubitemid 37548683)
20. Wang Y, Feinstein SI, Manevich Y, Ho YS, Fisher AB. Peroxiredoxin 6 gene-targeted mice show increased lung injury with paraquat-induced oxidative stress. Antioxid Redox Signal 2006; 8: 229-237. (Pubitemid 43324549)
21. Hu CD, Chinenov Y, Kerppola TK. Visualization of interactions among bZIP and Rel family proteins in living cells using bimolecular fluorescence complementation. Mol Cell 2002; 9: 789-798. (Pubitemid 34454889)
22. Chang XZ, Li DQ, Hou YF, Wu J, Lu JS, Di GH et al. Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer. Breast Cancer Res 2007; 9: R76.
23. Li DQ, Wang L, Fei F, Hou YF, Luo JM, Zeng R et al. Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry. Proteomics 2006; 6: 3352-3368. (Pubitemid 43886152)
24. Park JG, Yang HK, Kim WH, Chung JK, Kang MS, Lee JH et al. Establishment and characterization of human gastric carcinoma cell lines. Int J Cancer 1997; 70: 443-449. (Pubitemid 27107273)
25. Hamai A, Richon C, Meslin F, Faure F, Kauffmann A, Lecluse Y et al. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: relationship to Bcl-2 family and caspase activation. Oncogene 2006; 25: 7618-7634. (Pubitemid 44924475)
26. Zheng L, Schickling O, Peter ME, Lenardo MJ. The death effector domain-associated factor plays distinct regulatory roles in the nucleus and cytoplasm. J Biol Chem 2001; 276: 31945-31952.
27. McDonald III ER, El-Deiry WS. Suppression of caspase-8- and -10-associated RING proteins results in sensitization to death ligands and inhibition of tumor cell growth. Proc Natl Acad Sci USA 2004; 101: 6170-6175. (Pubitemid 38520546)
28. 2 activity. J Biol Chem 2006; 281: 7515-7525. (Pubitemid 43847522)
29. Gao L, Tse SW, Conrad C, Andreadis A. Saitohin, which is nested in the tau locus and confers allele-specific susceptibility to several neurodegenerative diseases, interacts with peroxiredoxin 6. J Biol Chem 2005; 280: 39268-39272. (Pubitemid 41713880)
30. Manevich Y, Reddy KS, Shuvaeva T, Feinstein SI, Fisher AB. Structure and phospholipase function of peroxiredoxin 6: identification of the catalytic triad and its role in phospholipid substrate binding. J Lipid Res 2007; 48: 2306-2318. (Pubitemid 47529572)
31. Choi K, Ryu SW, Song S, Choi H, Kang SW, Choi C. Caspase-dependent generation of reactive oxygen species in human astrocytoma cells contributes to resistance to TRAIL-mediated apoptosis. Cell Death Differ 2010; 17: 833-845.
32. Rinker-Schaeffer CW, O'Keefe JP, Welch DR, Theodorescu D. Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clin Cancer Res 2006; 12: 3882-3889. (Pubitemid 44078070)
33. Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 2003; 3: 55-63. (Pubitemid 37328887)
34. Shin MS, Kim HS, Lee SH, Park WS, Kim SY, Park JY et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res 2001; 61: 4942-4946.
35. Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF et al. Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand. Hum Pathol 2006; 37: 1286-1294. (Pubitemid 44380273)
36. Vigneswaran N, Wu J, Nagaraj N, Adler-Storthz K, Zacharias W. Differential susceptibility of metastatic and primary oral cancer cells to TRAIL-induced apoptosis. Int J Oncol 2005; 26: 103-112.
37. Stupack DG, Teitz T, Potter MD, Mikolon D, Houghton PJ, Kidd VJ et al. Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 2006; 439: 95-99. (Pubitemid 43053635)
38. Chang JW, Choi H, Kim HJ, Jo DG, Jeon YJ, Noh JY et al. Neuronal vulnerability of CLN3 deletion to calcium-induced cytotoxicity is mediated by calsenilin. Hum Mol Genet 2007; 16: 317-326. (Pubitemid 46323187)
39. Park Y, Hwang YP, Lee JS, Seo SH, Yoon SK, Yoon JB. Proteasomal ATPase-associated factor 1 negatively regulates proteasome activity by interacting with proteasomal ATPases. Mol Cell Biol 2005; 25: 3842-3853. (Pubitemid 40559588)
40. Kim IK, Chung CW, Woo HN, Hong GS, Nagata S, Jung YK. Reconstitution of caspase-8 sensitizes JB6 cells to TRAIL. Biochem Biophys Res Commun 2000; 277: 311-316.